Research ArticleSpecial Communications

Cannabis and Its Derivatives: Review of Medical Use

Lawrence Leung
The Journal of the American Board of Family Medicine July 2011, 24 (4) 452-462; DOI: https://doi.org/10.3122/jabfm.2011.04.100280

References

  1. ↵
    Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006; 28(2): 153–7.
    OpenUrlPubMed
  2. ↵
    Touw M. The religious and medicinal uses of Cannabis in China, India and Tibet. J Psychoactive Drugs 1981; 13(1): 23–34.
    OpenUrlPubMedWeb of Science
  3. ↵
    Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009; 374(9698): 1383–91.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001; 178: 101–6.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83(2): 393–411.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232(1): 54–61.
    OpenUrlPubMedWeb of Science
  7. ↵
    Egan D, Miron JA. The budgetary implications of marihuana prohibition. In: Earleywine M, ed. Pot Politics: Marijuana and the Costs of Prohibition. New York: Oxford University Press; 2007: 17–39.
  8. ↵
    Hoffmann DE, Weber E. Medical marijuana and the law. N Engl J Med 2010; 362(16): 1453–7.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    MacDonald J. Medical marijuana: informational resources for family physicians. Am Fam Physician 2009; 80(8): 779.
    OpenUrlPubMed
  10. ↵
    Aggarwal SK, Kyashna-Tocha M, Carter GT. Dosing medical marijuana: rational guidelines on trial in Washington State. Med Gen Med 2007; 9(3): 52.
    OpenUrl
  11. ↵
    O’Connell TJ, Bou-Matar CB. Long term marijuana users seeking medical cannabis in California (2001–2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants. Harm Reduct J 2007; 4: 16.
    OpenUrlCrossRefPubMed
  12. ↵
    Single E, Christie P, Ali R. The impact of cannabis decriminalisation in Australia and the United States. J Public Health Policy 2000; 21(2): 157–86.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    US Department of Veterans Affairs. Medical marijuana. VHA Directive 2010–035. Washington DC: Veterans Health Administration; July 2010. Available at: http://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=2276. Accessed.
  14. ↵
    Lifland JB. States reassess medical marijuana laws after warnings. 3 May 2011. Available at: http://yourlife.usatoday.com/health/medical/story/2011/05/States-reassess-medical-marijuana-laws-after-warnings/46756064/1#uslPageReturn. Accessed 31 May 2011.
  15. ↵
    Health Canada. Fact sheet–medical access to marihuana. 2008. Available at: http://www.hc-sc.gc.ca/dhp-mps/marihuana/law-loi/fact_sheet-infofiche-eng.php. Accessed 31 May 2011.
  16. ↵
    Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352(9140): 1611–6.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chem Biodivers 2007; 4(8): 1744–69.
    OpenUrlCrossRefPubMed
  18. ↵
    Moir D, Rickert WS, Levasseur G, et al. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem Res Toxicol 2008; 21(2): 494–502.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    Reid PT, Macleod J, Robertson JR. Cannabis and the lung. J R Coll Physicians Edinb 2010; 40(4): 328–34.
    OpenUrlPubMed
  20. ↵
    Tashkin DP. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis 2005; 63(2): 93–100.
    OpenUrlPubMed
  21. ↵
    Lehavi A, Shay M, Gilony C, Even L. [Marijuana smoking and paroxysmal atrial fibrillation]. Harefuah 2005; 144(1): 2–3, 72.
    OpenUrlPubMed
  22. ↵
    Baranchuk A, Johri AM, Simpson CS, Methot M, Redfearn DP. Ventricular fibrillation triggered by marijuana use in a patient with ischemic cardiomyopathy: a case report. Cases J 2008; 1(1): 373.
    OpenUrlPubMed
  23. Basnet S, Mander G, Nicolas R. Coronary vasospasm in an adolescent resulting from marijuana use. Pediatr Cardiol 2009; 30(4): 543–5.
    OpenUrlPubMed
  24. Bailly C, Merceron O, Hammoudi N, Dorent R, Michel PL. Cannabis induced acute coronary syndrome in a young female. Int J Cardiol 2010; 143(1): e4–6.
    OpenUrlPubMed
  25. ↵
    Dwivedi S, Kumar V, Aggarwal A. Cannabis smoking and acute coronary syndrome: two illustrative cases. Int J Cardiol 2008; 128(2): e54–7.
    OpenUrlPubMed
  26. ↵
    Kocabay G, Yildiz M, Duran NE, Ozkan M. Acute inferior myocardial infarction due to cannabis smoking in a young man. J Cardiovasc Med (Hagerstown) 2009; 10(9): 669–70.
    OpenUrlCrossRefPubMed
  27. ↵
    Cappelli F, Lazzeri C, Gensini GF, Valente S. Cannabis: a trigger for acute myocardial infarction? A case report. J Cardiovasc Med (Hagerstown) 2008; 9(7): 725–8.
    OpenUrlPubMed
  28. ↵
    Fergusson DM, Horwood LJ, Northstone K. Maternal use of cannabis and pregnancy outcome. BJOG 2002; 109(1): 21–7.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    Zuckerman B, Frank DA, Hingson R, et al. Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med 1989; 320(12): 762–8.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    English DR, Hulse GK, Milne E, Holman CD, Bower CI. Maternal cannabis use and birth weight: a meta-analysis. Addiction 1997; 92(11): 1553–60.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    van Gelder MM, Reefhuis J, Caton AR, Werler MM, Druschel CM, Roeleveld N. Characteristics of pregnant illicit drug users and associations between cannabis use and perinatal outcome in a population-based study. Drug Alcohol Depend 2010; 109(1–3): 243–7.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    Schempf AH, Strobino DM. Illicit drug use and adverse birth outcomes: is it drugs or context? J Urban Health 2008; 85(6): 858–73.
    OpenUrlCrossRefPubMed
  33. Le Bec PY, Fatseas M, Denis C, Lavie E, Auriacombe M. [Cannabis and psychosis: search of a causal link through a critical and systematic review]. Encephale 2009; 35(4): 377–85.
    OpenUrlCrossRefPubMed
  34. Shapiro GK, Buckley-Hunter L. What every adolescent needs to know: cannabis can cause psychosis. J Psychosom Res 2010; 69(6): 533–9.
    OpenUrlCrossRefPubMed
  35. ↵
    Dragt S, Nieman DH, Becker HE, et al. Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Can J Psychiatry 2010; 55(3): 165–71.
    OpenUrlPubMed
  36. ↵
    Miller NS, Gold MS. The diagnosis of marijuana (cannabis) dependence. J Subst Abuse Treat 1989; 6(3): 183–92.
    OpenUrlPubMed
  37. ↵
    Swift W, Gates P, Dillon P. Survey of Australians using cannabis for medical purposes. Harm Reduct J 2005; 2: 18.
    OpenUrlCrossRefPubMed
  38. ↵
    Latimer W, Zur J. Epidemiologic trends of adolescent use of alcohol, tobacco, and other drugs. Child Adolesc Psychiatr Clin N Am 2010; 19(3): 451–64.
    OpenUrlPubMed
  39. ↵
    McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W. Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies. Int J Drug Policy 2010; 21(1): 10–9.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    Degenhardt L, Coffey C, Carlin JB, Swift W, Moore E, Patton GC. Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in Victoria, Australia. Br J Psychiatry 2010; 196: 290–5.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Temple EC, Brown RF, Hine DW. The ‘grass ceiling’: limitations in the literature hinder our understanding of cannabis use and its consequences. Addiction 2011; 106(2): 238–44.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    Drug Enforcement Adminstration, US Department of Justice. Herbal high-legal synthetic cannabinoids produce illicit marijuana effects: spice, k2 and other “legal” products sold as marijuana alternatives. June 2010. Available at: www.wyptac.org/upload/DEA%20K2%20Fact%20Sheet.pdf. Accessed 31 May 2011.
  43. ↵
    Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 2010; 160(3): 585–93.
    OpenUrlCrossRefPubMedWeb of Science
  44. ↵
    Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004; 62(11): 2098–100.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 2003; 102(1–2): 211–6.
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008; 9(6): 506–21.
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010; 182(14): E694–701.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007; 68(7): 515–21.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009; 34(3): 672–80.
    OpenUrlCrossRefPubMedWeb of Science
  50. ↵
    Bushlin I, Rozenfeld R, Devi LA. Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol 2010; 10(1): 80–6.
    OpenUrlCrossRefPubMed
  51. ↵
    Yesilyurt O, Dogrul A, Gul H, et al. Topical cannabinoid enhances topical morphine antinociception. Pain 2003; 105(1–2): 303–8.
    OpenUrlCrossRefPubMedWeb of Science
  52. ↵
    Yesilyurt O, Dogrul A. Lack of cross-tolerance to the antinociceptive effects of systemic and topical cannabinoids in morphine-tolerant mice. Neurosci Lett 2004; 71(2–3): 122–7.
    OpenUrl
  53. ↵
    Elikkottil J, Gupta P, Gupta K. The analgesic potential of cannabinoids. J Opioid Manag 2009; 5(6): 341–57.
    OpenUrlPubMed
  54. ↵
    Cox ML, Haller VL, Welch SP. Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat. Eur J Pharmacol 2007; 567(1–2): 125–30.
    OpenUrlCrossRefPubMed
  55. Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 2006; 530(1–2): 54–8.
    OpenUrlCrossRefPubMed
  56. ↵
    Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 2004; 17(1): 59–67.
    OpenUrlCrossRefPubMed
  57. Sandyk R, Awerbuch G. Marijuana and Tourette’s syndrome. J Clin Psychopharmacol 1998; 8(6): 444–5.
    OpenUrl
  58. Hemming M, Yellowlees PM. Effective treatment of Tourette’s syndrome with marijuana. J Psychopharmacol 1993; 7(4): 389–91.
    OpenUrlAbstract/FREE Full Text
  59. Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 1980; 87(3): 222–8.
    OpenUrlPubMedWeb of Science
  60. Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007; 107(5): 785–96.
    OpenUrlCrossRefPubMedWeb of Science
  61. Kraft B, Frickey NA, Kaufmann RM, et al. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 2008; 109(1): 101–10.
    OpenUrlCrossRefPubMedWeb of Science
  62. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10(4): 417–24.
    OpenUrlAbstract/FREE Full Text
  63. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76(12): 1664–9.
    OpenUrlAbstract/FREE Full Text
  64. Muller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette’s syndrome with 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002; 35(2): 57–61.
    OpenUrlCrossRefPubMedWeb of Science
  65. Muller-Vahl KR, Schneider U, Prevedel H, et al. 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003; 64(4): 459–65.
    OpenUrlPubMed
  66. Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7(1): 39–50.
    OpenUrlPubMed
  67. Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral -9-tetrahydrocannabinol in postoperative pain. Pain 2003; 106(1–2): 169–72.
    OpenUrlCrossRefPubMedWeb of Science
  68. Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 2004; 8(2): 173–7.
    OpenUrlCrossRefPubMedWeb of Science
  69. Guzman M, Duarte MJ, Blazquez C, et al. A pilot clinical study of 9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006; 95(2): 197–203.
    OpenUrlCrossRefPubMed
  70. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 1997; 12(9): 913–9.
    OpenUrlCrossRefPubMedWeb of Science
  71. Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) 2006; 185(4): 524–8.
    OpenUrlCrossRefPubMed
  72. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10(2): 89–97.
    OpenUrlCrossRefPubMedWeb of Science
  73. Pooyania S, Ethans K, Szturm T, Casey A, Perry D. A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Arch Phys Med Rehabil 2010; 91(5): 703–7.
    OpenUrlPubMed
  74. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008; 9(2): 164–73.
    OpenUrlCrossRefPubMedWeb of Science
  75. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007; 133(1–3): 210–20.
    OpenUrlCrossRefPubMedWeb of Science
  76. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003; 17(1): 21–9.
    OpenUrlAbstract/FREE Full Text
  77. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65(6): 812–9.
    OpenUrlAbstract/FREE Full Text
  78. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis 2004; 10(4): 425–33.
    OpenUrlAbstract/FREE Full Text
  79. ↵
    Bocker KB, Gerritsen J, Hunault CC, Kruidenier M, Mensinga TT, Kenemans JL. Cannabis with high Delta(9)-THC contents affects perception and visual selective attention acutely: an event-related potential study. Pharmacol Biochem Behav 2010; 96(1): 67–74.
    OpenUrlPubMed
  80. ↵
    McLaren J, Swift W, Dillon P, Allsop S. Cannabis potency and contamination: a review of the literature. Addiction 2008; 103(7): 1100–9.
    OpenUrlCrossRefPubMedWeb of Science
  81. ↵
    Kagen SL, Kurup VP, Sohnle PG, Fink JN. Marijuana smoking and fungal sensitization. J Allergy Clin Immunol 1983; 71(4): 389–93.
    OpenUrlCrossRefPubMedWeb of Science
  82. ↵
    Kurup VP, Resnick A, Kagen SL, Cohen SH, Fink JN. Allergenic fungi and actinomycetes in smoking materials and their health implications. Mycopathologia 1983; 82(1): 61–4.
    OpenUrlCrossRefPubMedWeb of Science
  83. ↵
    Ungerleider JT, Andrysiak T, Tashkin DP, Gale RP. Contamination of marihuana cigarettes with pathogenic bacteria–possible source of infection in cancer patients. Cancer Treat Rep 1982; 66(3): 589–91.
    OpenUrlPubMed
  84. ↵
    Chusid MJ, Gelfand JA, Nutter C, Fauci AS. Pulmonary aspergillosis, inhalation of contaminated marijuana smoke, chronic granulomatous disease. Ann Intern Med 1975; 82(5): 682–3.
    OpenUrlPubMedWeb of Science
  85. ↵
    Exley C, Begum A, Woolley MP, Bloor RN. Aluminum in tobacco and cannabis and smoking-related disease. Am J Med 2006; 119(3): 276.e9–211.
    OpenUrlCrossRefPubMed
  86. ↵
    Shi G, Cai Q. Cadmium tolerance and accumulation in eight potential energy crops. Biotechnol Adv 2009; 27(5): 555–61.
    OpenUrlPubMed
  87. ↵
    Delourme J, Delattre C, Godard P, Steenhouwer F, Just N. [Respiratory consequences of inhalation of adulterated cannabis]. Rev Mal Respir 2009; 26(5): 552–6.
    OpenUrlPubMed
  88. ↵
    Viana M, Querol X, Alastuey A, et al. Drugs of abuse in airborne particulates in urban environments. Environ Int 2010; 36(6): 527–34.
    OpenUrlPubMed
  89. ↵
    Rohrich J, Schimmel I, Zorntlein S, et al. Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to Cannabis smoke in a coffee shop. J Anal Toxicol 2010; 34(4): 196–203.
    OpenUrlAbstract/FREE Full Text
  90. ↵
    Lister J. Cannabis controversy and other sundry troubles. N Engl J Med 1969; 280(13): 712–4.
    OpenUrlPubMed
  91. ↵
    Ren Y, Whittard J, Higuera-Matas A, Morris CV, Hurd YL. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci 2009; 29(47): 14764–9.
    OpenUrlAbstract/FREE Full Text
  92. ↵
    Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008; 30(3): 271–80.
    OpenUrlPubMed
  93. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006; 39(4): 421–9.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section